Development of high-throughput quantification and validation proteomic techniques which could be used in the analysis of clinical samples. Application of the state-of-the-art proteomic techniques in disease researches, especially the discovery of diagnostic/prognostic biomarkers and therapeutic targets of liver diseases for translational medicine.
A high-throughput technique platform for biomarker discovery and validation in clinical samples including tissues and body fluids was established.
A batch of important disease-related proteins with intellectual properties were discovered, including candidate serum markers for hepatocellular carcinoma (HCC) diagnosis and metastasis prognosis, and one potential target for HCC treatment. We participated in the CNHPP Project and are engaged in the development of assay kits for the clinical translation of these candidate molecules.
1. Characterization of the liver tissue interstitial fluid (TIF) proteome indicates potential for application in liver disease biomarker discovery. Journal of Proteome Research, 2010
2. Quantitative proteome analysis of HCC cell lines with different metastatic potentials by SILAC. Proteomics, 2008
3. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Molecular & Cellular Proteomics, 2007
4. Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. Proteomics, 2006
Please subscribe here for monthly updates from the Phoenix Center.